Accessibility Menu
Kairos Pharma logo

Kairos Pharma(NYSEMKT) KAPA

Market Cap$39.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-91%
5 YearN/A
1 Year-81%
1 Month-21%
$1.69
+1.60%
+0.03Today
After hours$1.71+$0.03 (+1.62%)
Kairos Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.242026-08-28
Kairos Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-18.24%USD 0.292026-08-21
1 month-20.7%USD 0.302026-07-29
3 month-53.46%USD 0.512026-05-29
Year to date-66.61%USD 0.712025-12-31
1 year-81.18%USD 1.262025-08-28
Since inception-90.88%USD 2.602024-09-16

Kairos Pharma Financials at a Glance

Market Cap

$39.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$5.81M

EPS (TTM)

-$0.28

P/E Ratio

-6.04

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$1.69

Volume

53,529.857

Open

$1.69

Previous Close

$1.68

Daily Range

$1.64 - $1.75

52-Week Range

$1.54 - $14.77

Estimated Earnings Date

Nov 13, 2026

KAPA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kairos Pharma

Kairos Pharma develops medicines for cancer patients with few treatment options. Its therapies aim to help people with prostate, lung, and brain cancers. The company focuses on new ways to fight drug resistance and immune system suppression in cancer.

Lab Coats & Cancer: What Kairos Sells

  • Antibody Therapies: Medicines that target cancer cells in prostate and lung cancer (0% of revenue; no sales yet).
  • Small Molecule Drugs: Chemical treatments for solid tumors and immune system targets (0% of revenue).
  • T Cell Therapy: Uses a patient’s own immune cells to attack brain tumors (0% of revenue).
  • Companion Diagnostics: Tests to help match patients with the right treatment (0% of revenue).
  • Pipeline Portfolio: Seven drug candidates for different cancer types and resistance problems (0% of revenue).

Growth Spurts & Strategic Moves

  • Acquired Enviro Therapeutics in 2021, adding two new drug candidates.
  • Launched Phase 2 trial for ENV 105 in prostate cancer in 2023.
  • Secured $3.2 million NIH grant for biomarker development in 2024.
  • Signed exclusive technology licenses with Cedars-Sinai Medical Center since 2016.
  • Entered equity line of credit with Helena Global Investment Opportunities in 2024.

Why Kairos Is a Bit Different

Kairos runs a lean operation, relying on academic partners and outside vendors. Its drug pipeline covers several cancer types and targets drug resistance. The company uses licensed technology to access new drug targets and methods.

Five Things You Need to Know

  • No revenue reported for 2025, 2024, or 2023.
  • Net loss was $5.45 million in 2025, up 109.3% from 2024.
  • Research and development expense rose 415% to $2.14 million in 2025.
  • Cash used in operations was $3.44 million in 2025, down 13.0% from 2024.

Bottom Line

Kairos remains a research-focused biotech with no commercial products and rising R&D spending. Its future depends on advancing its drug pipeline and securing new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

John S. Yu, MD

Website

kairospharma.com

Headquarters

Los Angeles, CA 90064, US

KAPA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-98.77%

Return on Capital

-87.87%

Return on Assets

-130.27%

Earnings Yield

-16.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.70M

Volume

53.53K

Avg. Volume

311.96K

Financials (TTM)

Gross Profit

$80.00K

Operating Income

-$6.03M

EBITDA

-$5.66M

Operating Cash Flow

-$3.97M

Capital Expenditure

$0.00

Free Cash Flow

-$3.97M

Cash & ST Invst.

$2.63M

Total Debt

$0.00

Kairos Pharma Performance Analysis

Kairos Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Kairos Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Kairos Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.08-51.1%
20232023-12-31USD -0.1472.6%
20242024-12-31USD -0.1934.4%
20252025-12-31USD -0.3056.0%
Kairos Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3015.3%
Q42025-12-313.0%
Q12026-03-31-15.9%
Q22026-06-3023.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$39.81MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.95M

N/A

Employees

4

N/A

Net Income

-$1.39M

+2.4%

EBITDA

-$1.37M

+1.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.63M

-13.4%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.30%

N/A

Return on Invested Capital

-1.44%

N/A

Free Cash Flow

-$1.01M

-25.7%

Operating Cash Flow

-$1.01M

-25.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCTXBriaCell Therapeutics Corp.
$3.59-3.75%
ALLRAllarity Therapeutics, Inc.
$1.41+0.00%
ENTOEntero Therapeutics, Inc.
$2.85-5.00%
CINGCingulate Inc.
$5.17-2.91%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About KAPA

What is the current price of Kairos Pharma?

Kairos Pharma is trading at $1.68 per share.

What is the 52-week range for Kairos Pharma?

Over the past 52 weeks, Kairos Pharma has traded between $1.54 and $14.77.

How much debt does Kairos Pharma have?

As of the most recent reporting period, Kairos Pharma reported total debt of $0.00.

How much cash does Kairos Pharma have on hand?

Kairos Pharma reported $2.63M in cash and cash equivalents in its most recent financial results.

What is Kairos Pharma’s dividend yield?

Kairos Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services